Liquidia Valuation
Is LT4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LT4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LT4 (€9.6) is trading below our estimate of fair value (€55.69)
Significantly Below Fair Value: LT4 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LT4?
Key metric: As LT4 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is LT4's PB Ratio? | |
|---|---|
| PB Ratio | 8.2x |
| Book | US$110.52m |
| Market Cap | US$901.38m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 52.1x |
| Enterprise Value/EBITDA | -7.4x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does LT4's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.1x | ||
DMP Dermapharm Holding | 3.5x | 18.1% | €2.0b |
PSG PharmaSGP Holding | 8.6x | 13.9% | €280.6m |
2FJ0 Pierrel | 3.6x | n/a | €92.8m |
0RX Redx Pharma | 16.6x | -22.3% | €65.0m |
LT4 Liquidia | 8.2x | 59.6% | €901.4m |
Price-To-Book vs Peers: LT4 is expensive based on its Price-To-Book Ratio (8.2x) compared to the peer average (8.1x).
Price to Book Ratio vs Industry
How does LT4's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 12 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: LT4 is expensive based on its Price-To-Book Ratio (8.2x) compared to the European Pharmaceuticals industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is LT4's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 8.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate LT4's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €9.60 | €24.10 +151.1% | 18.2% | €29.36 | €16.10 | n/a | 9 |
| Nov ’25 | €9.84 | €23.27 +136.5% | 17.8% | €27.56 | €15.61 | n/a | 9 |
| Oct ’25 | €8.88 | €21.78 +145.5% | 17.7% | €26.32 | €15.43 | n/a | 7 |
| Sep ’25 | €8.57 | €21.57 +151.9% | 17.7% | €26.07 | €15.28 | n/a | 7 |
| Aug ’25 | €10.97 | €25.52 +132.7% | 11.6% | €29.52 | €21.22 | n/a | 6 |
| Jul ’25 | €11.38 | €22.19 +95.0% | 37.8% | €29.41 | €2.76 | n/a | 7 |
| Jun ’25 | €11.73 | €22.19 +89.1% | 37.8% | €29.41 | €2.76 | n/a | 7 |
| May ’25 | €11.53 | €23.45 +103.4% | 36.8% | €29.85 | €2.80 | n/a | 7 |
| Apr ’25 | €13.78 | €21.91 +59.0% | 38.8% | €29.39 | €2.76 | n/a | 7 |
| Mar ’25 | €13.02 | €19.54 +50.1% | 42.9% | €27.73 | €2.77 | n/a | 7 |
| Feb ’25 | €11.76 | €19.19 +63.2% | 44.2% | €27.60 | €2.76 | n/a | 7 |
| Jan ’25 | €10.76 | €16.62 +54.5% | 46.4% | €27.27 | €2.73 | n/a | 7 |
| Dec ’24 | €6.49 | €13.13 +102.3% | 34.1% | €16.88 | €2.81 | n/a | 7 |
| Nov ’24 | €6.08 | €13.27 +118.3% | 34.1% | €17.06 | €2.84 | €9.84 | 7 |
| Oct ’24 | €5.96 | €13.05 +119.0% | 34.1% | €16.78 | €2.80 | €8.88 | 7 |
| Sep ’24 | €6.28 | €12.79 +103.6% | 34.1% | €16.44 | €2.74 | €8.57 | 7 |
| Aug ’24 | €6.96 | €12.70 +82.5% | 34.1% | €16.33 | €2.72 | €10.97 | 7 |
| Jul ’24 | €7.44 | €13.09 +76.0% | 35.4% | €18.33 | €2.75 | €11.38 | 7 |
| Jun ’24 | €7.52 | €13.03 +73.3% | 35.4% | €18.24 | €2.74 | €11.73 | 7 |
| May ’24 | €5.98 | €13.04 +118.1% | 35.4% | €18.26 | €2.74 | €11.53 | 7 |
| Apr ’24 | €6.13 | €13.33 +117.5% | 35.4% | €18.66 | €2.80 | €13.78 | 7 |
| Mar ’24 | €7.08 | €13.12 +85.2% | 35.0% | €18.74 | €2.81 | €13.02 | 7 |
| Feb ’24 | €6.00 | €13.05 +117.5% | 39.3% | €19.85 | €2.98 | €11.76 | 7 |
| Jan ’24 | €6.01 | €13.05 +117.2% | 39.3% | €19.85 | €2.98 | €10.76 | 7 |
| Dec ’23 | €4.75 | €13.05 +175.0% | 39.3% | €19.85 | €2.98 | €6.49 | 7 |
| Nov ’23 | €4.86 | €13.36 +174.7% | 38.1% | €20.11 | €3.02 | €6.08 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
5.1%
1Y
22.9%